SQI closes second tranche of private placement

SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today it has raised gross proceeds of CDN $2.333 million through the second tranche of a non-brokered private placement (the "Private Placement") of 1,333,428 units ("Units") priced at $1.75 per Unit. The aggregate gross proceeds raised by the Company in connection with both the first and the second tranche is $4.905 million.

Each Unit consists of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at a price of $2.50 for a period of two years from the date of issuance. After giving effect to the issuance of the shares and assuming the exercise of all warrants issued in connection with both the first and second tranches of the Private Placement the Company would have 41,886,309 shares outstanding.

In connection with the second tranche of the Private Placement, the Company paid Kingsdale Capital Markets Inc. ("Kingsdale") a cash finder's fee of $140,010 and issued 80,006 compensation warrants entitling Kingsdale to acquire 80,006 Units at a price of $1.75 per Unit and expiring 24 months after the closing of the Offering.

In addition, the Company now expects to complete the previously announced private placement of up to 5,142,847 units at a price of $1.75 per Unit for gross proceed of up to $9 million in three tranches. The third tranche is expected to close on or about May 24, 2012.

The Private Placement is subject to all necessary regulatory and stock exchange approvals. The securities being issued pursuant to the Private Placement will be subject to a four month hold period in accordance with applicable Canadian securities law.

SQI intends to use the net proceeds to fund the Company's product development and commercialization programs, sales and marketing and for general working capital purposes.

"The closing of the second tranche of the Private Placement is important to the Company as we believe that it puts the Company in a strong position to focus on our sales funnel of Diagnostic Tools and Services and continue to commercialize our IVD products which will strengthen our IVD customer opportunities," said Andrew Morris, Chief Financial Officer of SQI.

Source:

SQI Diagnostics    

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Digital spatial profiling of individual glomeruli from HIV and COVID-19 patients